Myocarditis following COVID-19 mRNA vaccination.

Messenger RNA vaccines are the main COVID-19 vaccines authorized for use in the United States. Side effects are typically minor and transient. We report a case series of four subjects with an acute myocarditis-like illness following mRNA COVID-19 vaccination who were hospitalized at our hospital in Lubbock, Texas. Three patients were young men who presented with acute chest pain after the second dose of the mRNA-1273 vaccine. Another patient was a 53-year-old white woman who presented with acute left arm pain 3 days after the first dose of the mRNA-1273 vaccine. She was later found to have acute decompensated heart failure, and endomyocardial biopsy revealed eosinophilic injury-mediated myocarditis.

The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a major effect on our lives globally. SARS-CoV-2 vaccines significantly reduce the risk of contracting COVID-19 illness., The US Food and Drug Administration provided an emergent use authorization for two mRNA COVID-19 vaccines from Moderna (mRNA-1273) and Pfizer-BioNTech (BNT162b2). Side effects are typically minor and transient. Recently, the safety committee of the US Centers for Disease Control and Prevention stated that there was a likely association between SARS-CoV-2 vaccines and myocarditis/pericarditis. We report four adult patients who were confirmed to have myocarditis/pericarditis following SARS-CoV-2 vaccination.

CASE DESCRIPTION

A total of four patients were hospitalized at our hospital in Lubbock, Texas, in early 2021 for myocarditis following mRNA-1273 vaccination. The clinical characteristics of the patients are shown in . Three patients (Cases 2–4) were young white men and presented with hemodynamically stable chest pain. One woman (Case 1) presented with left arm pain that started 3 days after the first dose of vaccine. She was hemodynamically unstable and found to have findings of acute decompensated heart failure on admission.

All patients had a negative Sofia 2 SARS Antigen Fluorescent Immunoassay test (Quidel Corporation, San Diego, CA). Electrocardiography upon arrival to the hospital was abnormal in three patients, as shown in . Serological tests for common viral myocarditis/pericarditis were negative for acute infection. Definitive diagnosis of acute myocarditis was made by endomyocardial biopsy in Case 1 (, whereas Cases 2 and 3 had a combination of clinical manifestations and typical cardiac magnetic resonance imaging abnormalities used for diagnosis of myocarditis (. We used clinical diagnostic criteria from the 2013 European Society of Cardiology for Case 4: new-onset acute chest pain with diffuse ST elevation and high-sensitivity cardiac troponin T.

Endomyocardial biopsy showing a polymorphous (mixed) active myocarditis with lymphohistiocytic inflammation and increased eosinophils (b, arrowheads). Myocyte injury was diffuse throughout the sampled tissue (b, arrow). No giant cells were identified throughout extensive sectioning of the biopsy, but vaguely granulomatous inflammation was apparent. (a, 40× original magnification, and b, 400× original magnification; both hematoxylin and eosin stain).

Cardiac magnetic resonance imaging of Cases 1–3 in short axis (first column), two-chamber (second column), and four-chamber (third column) views. Case 1: Mild late gadolinium enhancement (LGE) is seen in the inferolateral region in the pericardium in all views (arrow). Case 2: LGE is seen in the mid wall region in a multifocal distribution in all views (arrows and arrowheads). Case 3: LGE is seen in the inferolateral and lateral wall in all views (arrows and arrowheads).

Patients were initially treated with oral colchicine and ibuprofen. Because of a lack of clinical improvement, a decision was made to give high-dose intravenous methylprednisolone for 3 to 8 days. Cardiac markers improved significantly after corticosteroid initiation (. On clinic follow-up at 4 to 6 weeks, patients’ clinical status was stable, and they had normal high-sensitivity cardiac troponin T levels. Cases were reported to the Vaccine Adverse Event Reporting System.

DISCUSSION

Pericarditis and myocarditis following vaccination are rare, and most case reports have described self-limited and benign conditions. The rate of myocarditis/pericarditis following mRNA vaccines is about 8.6 cases per million doses among those aged 16 to 39 years. Myocarditis/pericarditis following the second dose was found more often than after the first dose (2.8 vs. 16.1 cases per million doses). Interestingly, among the two mRNA vaccines available in the US, the BNT162b2 vaccine has a lower rate of myocarditis/pericarditis than the mRNA-1273 vaccine (10.4 vs. 24.7 cases per million of the second doses).

Two recent published case series reported successful conservative therapies in most patients., However, our patients symptomatically improved with systemic corticosteroids, which is similar to a case from Verma et al. An endomyocardial biopsy performed in Case 1 revealed lymphocytic-eosinophilic injury–mediated myocarditis, which is similar to myocarditis related to smallpox vaccination., Moreover, Verma et al recently reported pathological findings with fulminant myocarditis after mRNA-1273 vaccinations that showed inflammatory infiltrate admixed with macrophages, T cells, eosinophils, and B cells. These findings suggest that the primary mechanism of myocardial injury may be from a maladaptive immune response and could respond to immunosuppressive therapy. A recent study by Muthukumar et al reported that patients with myocarditis following COVID-19 mRNA vaccination had an increase in a specific subset of NK cells and several autoantibodies compared with controls. However, a cardiac biopsy from one patient reported by Larson et al showed no myocardial infiltration.

This small case series is not conclusive that COVID-19 vaccination was the cause of myocarditis, as we could not completely exclude spontaneous myocarditis from other causes in these patients. The medical community continues to advocate for universal COVID-19 vaccination in society. Overall, further research and monitoring for adverse events will lead to best treatment practices related to COVID-19 vaccination.

Click here for additional data file.

Table 1.

Characteristics and outcomes of patients with myocarditis following COVID-19 vaccination

Variable	Case number				Reference value
	1	2	3	4
Age (years)	53	22	19	22
Gender	Female	Male	Male	Male
Race/ethnicity	White	White	White	White
Comorbidities	Depression, hyperlipidemia	Asthma, kidney stone	None	Asthma, fibrous dysplasia
Vaccine type	mRNA-1273	mRNA-1273	mRNA-1273	mRNA-1273
Vaccine dose	First	Second	Second	Second
Days: vaccine to hospital	6	3	4	3
Body mass index (kg/m2)	28.7	34.9	28	24
Vital signs on arrival
Temperature (°F)	96.8	99.5	99.6	98.7
Heart rate (beats/min)	112	84	76	138
Blood pressure (mm Hg)	86/60	152/79	119/69	119/69
Respiratory rate (breaths/min)	17	22	14	20
Chest x-ray	Enlarged cardiac silhouette	Enlarged cardiac silhouette	Normal	Normal
Electrocardiogram	1st AV block; 3rd AV block later	Normal	Diffuse ST elevations	Diffuse ST elevation
Echocardiogram
Day from admission	2	2	1	2
LVEF (%)	60–64	55–59	65–69	60–64	≥55
TAPSE (cm)	2.1	1.9	2	2	<1.7
Right heart catheterization
Day from admission	4	1	Not done	Not done
RA pressure (mm Hg)	26	8			2.0–6.0
RV pressure (mm Hg)
Systolic	40	30			15–25
Diastolic	11	8			0–8
PA pressure (mm Hg)
Systolic	44	23			15–25
Diastolic	23	14			8.0–15.0
PCWP	29	12			6.0–12.0
Cardiac output (L/min)	3.54	7			4.0–8.0
Cardiac index (min × m2)	1.82	2.7			2.5–4.0
Cardiac MRI
Day after presentation	8	5	3	25
LVEF (%)	45	60	53	54
RVEF (%)	35	44	46	45
LGE abnormality	0	+	+	0
Increased T2 signal	0	+	0	0
Laboratory tests
WBC (K/µL)	14	11.54	5.73	23.4	4.23–9.07
Hemoglobin (g/dL)	11.2	15	15.8	15.5	13.7–17.5
Platelet count (K/µL)	379	202	230	288	163–337
BUN (mg/dL)	20	11	11	14	6.0–20.0
Creatinine (mg/dL)	0.8	0.8	0.9	1	0.5–1.2
Creatine kinase (IU/L)	340 (day 1)	421 (day 3)	1747 (day 1)	111 (day 1)	26–308
hs-cTnT (ng/L)					≤19.0
At presentation	1582	958	1509	90.3
Peak	1582 (day 1)	1254 (day 4)	2472 (day 2)	90.3 (day 1)
At discharge	41.5 (day 12)	195 (day 8)	210.6 (day 8)	25.6 (day 4)
At follow-up (weeks after discharge)	<6 (2 weeks)	16.3 (5 weeks)	13.1 (1 week)	N/A
Pro-BNP (pg/mL)	9401 (day 1)	400 (day 1)	149 (day 6)	730	≤124
Peak Pro-BNP (pg/mL)	14,933 (day 7)	400 (day 1)	149 (day 6)	730 (day 1)
D-dimer (ng/mL)	684	N/A	N/A	N/A	≤500
ESR (mm/h)					0–30
Initial	12 (day 4)	14 (day 1)	15 (day 2)	29 (day 1)
Peak	21 (day 12)	14 (day 1)	15 (day 2)	29 (day 1)
CRP (mg/dL)					0.0–0.5
Initial	15 (day 4)	5.4 (day 1)	3.1 (day 2)	7 (day 1)
Peak	15 (day 4)	5.4 (day 1)	3.1 (day 2)	12.4 (day 2)
Total bilirubin (mg/dL)	0.4	0.3	0.5	0.7	0.0–1.0
AST (IU/L)	160	72	30	25	5.0–37.0
ALT (IU/L)	169	41	78	32	5.0–41.0
ALP (IU/L)	58	56	78	136	35–129
Ferritin (ng/mL)	14,345 (day 11)	234 (day 6)	92.7 (day 2)	NA	13–150
TSH (µIU/mL)	0.08	2.94	0.23	1.86	0.27–4.20
Free T4 (ng/mL)	1.47	1.23	1.15	1.24	0.93–1.70
Lactate (mmol/L)	3.2	NA	NA	1.4	0.5–2.2
ANA	Negative	Negative	Negative	Not done
Ig E (IU/mL)	104	Not done	Not done	Not done	1.53–114
Clinical course
Hospitalization (days)	11	8	7	4
Methylprednisolone protocol	+	+	+	+
IV immunoglobulin	+	0	+	0

ALT indicates alanine transaminase; ANA, antinuclear antibodies; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; hs-cTnT, high-sensitivity cardiac troponin T; IV, intravenous; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; MRI, magnetic resonance imaging; PA, pulmonary artery; PCWP, pulmonary capillary wedge pressure; Pro-BNP, pro-brain natriuretic peptide; RA, right atrial; RV, right ventricular; RVEF, right ventricular ejection fraction; TAPSE, tricuspid annular plane systolic excursion; TSH, thyroid-stimulating hormone; WBC, white blood cell.